MA50805B1 - Formes cristallines de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide - Google Patents

Formes cristallines de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide

Info

Publication number
MA50805B1
MA50805B1 MA50805A MA50805A MA50805B1 MA 50805 B1 MA50805 B1 MA 50805B1 MA 50805 A MA50805 A MA 50805A MA 50805 A MA50805 A MA 50805A MA 50805 B1 MA50805 B1 MA 50805B1
Authority
MA
Morocco
Prior art keywords
quinoleine
cyclopropylmethyl
sulfonamide
piperazine
carbonyl
Prior art date
Application number
MA50805A
Other languages
English (en)
Other versions
MA50805A (fr
Inventor
Jacob Sizemore
Liting Guo
Mahmoud Mirmehrabi
Yeqing Su
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Priority claimed from PCT/US2018/062197 external-priority patent/WO2019104134A1/fr
Publication of MA50805A publication Critical patent/MA50805A/fr
Publication of MA50805B1 publication Critical patent/MA50805B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formes de sel d'hémisulfate amorphes et cristallines de formule. L'invention concerne également des compositions pharmaceutiques comprenant les formes de sel d'hémisulfate amorphes et cristallines, des procédés pour leur fabrication, et leurs utilisations pour traiter des états pathologiques associés à une pyruvate kinase, par exemple, une déficience en pyruvate kinase.
MA50805A 2017-11-22 2018-11-21 Formes cristallines de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide MA50805B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
PCT/US2018/062197 WO2019104134A1 (fr) 2017-11-22 2018-11-21 Formes cristallines de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide

Publications (2)

Publication Number Publication Date
MA50805A MA50805A (fr) 2020-09-30
MA50805B1 true MA50805B1 (fr) 2023-08-31

Family

ID=88016834

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50805A MA50805B1 (fr) 2017-11-22 2018-11-21 Formes cristallines de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide

Country Status (1)

Country Link
MA (1) MA50805B1 (fr)

Also Published As

Publication number Publication date
MA50805A (fr) 2020-09-30

Similar Documents

Publication Publication Date Title
MX2022009998A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.
EA202092580A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MX2020001403A (es) Nuevos derivados de quinolina.
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MD3442972T2 (ro) Inhibitori ai bromodomeniului
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA202092581A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40225A (fr) Composés dihydroisoquinolinone substitués
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
MA38391B1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
NO20083207L (no) Inhibitorer av IAP
EA202191519A1 (ru) Модуляторы trex1
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
MX2020011873A (es) Nuevos derivados de quinolina.
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
NZ631388A (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit